Details for Patent: 7,361,676

Which drugs does patent 7,361,676 protect, and when does it expire?

Patent 7,361,676 protects ULORIC and is included in one NDA.

This patent has fifteen patent family members in twelve countries.

Summary for Patent: 7,361,676

Title:	Solid preparation containing single crystal form
Abstract:	There are provided a solid preparation containing a single crystal of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid, an excipient and a disintegrating agent, and a method for producing the same.
Inventor(s):	Iwai; Michio (Osaka, JP), Nakamura; Kazuhiro (Yamaguchi, JP), Dohi; Masahiko (Tokyo, JP), Mochizuki; Hiroko (Yamaguchi, JP), Mochizuki; Seiji (Yamaguchi, JP)
Assignee:	Teijin Limited (Osaka, JP)
Application Number:	10/503,391
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,361,676
Patent Claim Types: see list of patent claims	Composition; Compound; Dosage form; Use;

Drugs Protected by US Patent 7,361,676

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Takeda Pharms Usa	ULORIC	febuxostat	TABLET;ORAL	021856-001	Feb 13, 2009	AB	RX	Yes	No			Y
Takeda Pharms Usa	ULORIC	febuxostat	TABLET;ORAL	021856-002	Feb 13, 2009	AB	RX	Yes	Yes			Y

Foreign Priority and PCT Information for Patent: 7,361,676

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Japan	2002-090889	Mar 28, 2002

PCT Information
PCT Filed	March 28, 2003	PCT Application Number:	PCT/JP03/03962
PCT Publication Date:	October 09, 2003	PCT Publication Number:	WO03/082279

International Family Members for US Patent 7,361,676

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1488790		C20140037 00152	Estonia
Australia	2003220909
Canada	2474674